Fox Chase Cancer Center News

PHILADELPHIA (March 11, 2021)—According to research by Daniel M. Geynisman, MD, associate professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium, some patients with muscle-invasive urothelial carcinoma, a form of bladder cancer, may not need to have their bladder removed.

PHILADELPHIA (March 11, 2021) – A nursing team at Fox Chase Cancer Center has been honored as a recipient of the 2021 I AM Patient Safety award from the Patient Safety Authority. The team was awarded the Executive Director’s Choice award, making it one of 11 healthcare facilities in Pennsylvania to be recognized for their advancements, outcomes, and commitment to patient safet

PHILADELPHIA (March 10, 2021)—Jennifer Barsky Reese, PhD, associate professor for the Cancer Prevention and Control Program at Fox Chase Cancer Center, was recently recognized with the New Investigator Award from the American Psychosocial Oncology Society (APOS).

PHILADELPHIA (March 10, 2021)— Researchers from Fox Chase Cancer Center have demonstrated that fitness trackers such as Fitbit are feasible tools for assessing performance status—the ability to perform activities of daily living—in colorectal cancer patients. The finding is important because performance status is used to determine whether cancer patients may tolerate more or less aggressive forms of treatment and how they are holding up during treatment.

PHILADELPHIA (March 3, 2021)—Margie L. Clapper, PhD, co-leader of Fox Chase Cancer Center’s Cancer Prevention and Control Program, has been awarded a grant by the Prevent Cancer Foundation to investigate the use of atorvastatin, also known by the brand name Lipitor, to prevent cancer in patients with Lynch syndrome. Clapper will be working with Michael J. Hall, MD, MS, co-leader of Fox Chase’s Cancer Prevention and Control Program, on the project. 

PHILADELPHIA (March 2, 2021)—Fox Chase Cancer Center has launched a new Cancer Epigenetics Institute (CEI) that will create a locally based national hub for epigenetics study and collaboration focused on mechanisms promoting cancer and therapeutic resistance.

PHILADELPHIA (February 22, 2021)—Kristen D. Whitaker, MD, MS, assistant professor in the Department of Clinical Genetics at Fox Chase Cancer Center, recently received a grant from the V Foundation for Cancer Research to study ways of improving diversity in clinical cancer trials. The grant was funded by Hooters of America, LLC.

PHILADELPHIA (February 15, 2021) – Researchers at Fox Chase Cancer Center have helped to identify a cellular resilience mechanism through which acute myeloid leukemia (AML) cells survive cancer treatment and repopulate leukemia, causing disease relapse. The research also suggests that certain drugs could be used to destroy these treatment-surviving AML cells.